ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.

被引：5

作者：

Mirza, Mansoor Raza

Mortensen, Christiane Ehlers

Avall-Lundqvist, Elisabeth

Bjorge, Line

Berek, Jonathan S.

Herrstedt, Jorn

Holm, Anne Juul

Kirkegaard, Tinne

Maenpaa, Johanna

机构：

[1] Copenhagen Univ Hosp, NSGO, Copenhagen, Denmark

[2] Copenhagen Univ Hosp, Copenhagen, Denmark

[3] Linkoping Univ, Dept Oncol, Linkoping, Sweden

[4] Linkoping Univ, Dept Clin Expt Med, Linkoping, Sweden

[5] Karolinska Inst, Linkoping, Sweden

[6] Dept Obstet & Gynecol, Bergen, Norway

[7] Stanford Womens Canc Ctr, Stanford, CA USA

[8] Odense Univ Hosp, DK-5000 Odense, Denmark

[9] NSGO, Copenhagen, Denmark

[10] Tampere Univ Hosp, Tampere, Finland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.tps5607

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS5607

引用

页数：1

共 45 条

[1] Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Mirza, Mansoor Raza
Lundqvist, Elisabeth Avail
Birrer, Michael
Christensen, Rene DePont
Nyvang, Gitte-Bettina
Malander, Susanne
Anttila, Maarit
Werner, Theresa L.
Lund, Bente
Lindahl, Gabriel
Hietanen, Sakari
Peen, Ulla
Dimoula, Maria
Roed, Henrik
Knudsen, Anja Or
Staff, Synnove
Vistisen, Anders Krog
Bjorge, Line
Maenpaa, Johanna U.
LANCET ONCOLOGY, 2019, 20 (10): : 1409 - 1419
[2] Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24.
Mirza, Mansoor Raza
Avall-Lundqvist, Elisabeth
Birrer, Michael J.
Christensen, Rene dePont
Nyvang, Gitte-Bettina
Malander, Susanne
Anttila, Maarit
Werner, Theresa Louise
Lund, Bente
Lindahl, Gabriel
Hietanen, Sakari
Peen, Ulla
Dimoula, Maria
Roed, Henrik
Knudsen, Anja Or
Boufercha, Louisa
Staff, Synnove
Vistisen, Anders Krog
Bjorge, Line
Maenpaa, Johanna Unelma
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
Mansoor Raza Mirza
Troels K. Bergmann
Morten Mau-Sørensen
René dePont Christensen
Elisabeth Åvall-Lundqvist
Michael J. Birrer
Morten Jørgensen
Henrik Roed
Susanne Malander
Flemming Nielsen
Ulrik Lassen
Kim Brøsen
Line Bjørge
Johanna Mäenpää
Cancer Chemotherapy and Pharmacology, 2019, 84 : 791 - 798
[4] A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
Mirza, Mansoor Raza
Bergmann, Troels K.
Mau-Sorensen, Morten
Christensen, Rene dePont
Avall-Lundqvist, Elisabeth
Birrer, Michael J.
Jorgensen, Morten
Roed, Henrik
Malander, Susanne
Nielsen, Flemming
Lassen, Ulrik
Brosen, Kim
Bjorge, Line
Maenpaa, Johanna
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 791 - 798
[5] A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
Mirza, Mansoor Raza
Mortensen, Christiane Ehlers
Christensen, Rene dePont
Christoffersen, Louise
Westergaard, Mia
Boufercha, Louisa
Birrer, Michael
Avail-Lundqvist, Elisabeth
Bjorge, Line
Maenpaa, Johanna Unelma
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer-A randomized controlled chemotherapy-free study.
Mirza, Mansoor Raza
Nyvang, Gitte-Betina
Lund, Bente
Christensen, Rene dePont
Werner, Theresa Louise
Malander, Susanne
Bjorge, Line
Birrer, Michael J.
Antiila, Maarit
Lindahl, Gabriel
Hietanen, Sakari
Dimoula, Maria
Peen, Ulla
Madsen, Kristine
Knudsen, Anja
Staff, Synnove
Vinum, Nicole Buchner
Kjelsen, Maj Kamille
Avall-Lundqvist, Elisabeth
Maenpaa, Johanna Unelma
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[7] A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)
Mirza, M. R.
Wang, J.
Mau-Sorensen, M.
Birrer, M. J.
Wang, X.
Jorgensen, M.
Zhang, Z-Y.
Roed, H.
Malander, S.
Nielsen, F.
Bjorge, L.
Lassen, U.
Boufercha, L.
Brosen, K.
Kansra, V.
Maenpaa, J.
ANNALS OF ONCOLOGY, 2017, 28
[8] ENGOT-OV16/NOVA: A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER
Matulonis, U.
Herrstedt, J.
Oza, A.
Mahner, S.
Redondo, A.
Fabbro, M.
Ledermann, J.
Lorusso, D.
Vergote, I.
Rosengarten, O.
Reinthaller, A.
Madry, R.
Monk, B. J.
Dorum, A.
Tinker, A. V.
DuBois, A.
Gonzalez Martin, A.
Follana, P.
Berek, J. S.
Gilbert, L.
Benigno, B.
Rosenberg, P.
Rimel, B. J.
Buscema, J.
Balser, J.
Agarwal, S.
Mirza, M. R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 19 - 20
[9] Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer
Moore, Kathleen
Chan, John K.
Secord, Angeles Alvarez
Patel, Manish R.
Callahan, Timothy
Guo, Wei
Zhang, Zhi-Yi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (04) : 717 - 726
[10] Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer
Kathleen Moore
John K. Chan
Angeles Alvarez Secord
Manish R. Patel
Timothy Callahan
Wei Guo
Zhi-Yi Zhang
Cancer Chemotherapy and Pharmacology, 2019, 83 : 717 - 726

← 1 2 3 4 5 →